EchoGen ultrasound contrast agent data

The Bothell, Wash., company announced that preliminary Phase II results are showing visualization of myocardial perfusion. Imaging of the heart's muscle blood flow was enhanced 300 percent by the agent in eight of 11 patients enrolled so far in the 50-patient trial. No adverse reactions appeared. ...